MSNBC (08/15/12) Bazell, Robert
The New England Journal of Medicine has published the results of a study of a prostate cancer drug that some say represents a significant advance in the fight against the disease. The study found that men with advanced prostate cancer who were given the drug enzalutamide, which is made by Medivation and is expected to be approved by the Food and Drug Administration within the next several months, lived an average of 18.4 months while taking the medication compared with 13.6 months for men who took a placebo. This was despite the fact that the prostate cancer patients who were given enzalutamide did not experience improvements while undergoing other forms of treatment. In addition, the study found that enzalutamide does not have the same side effects as chemotherapy.